Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide + anti-CD20 monoclonal antibody + CHOP for newly diagnosed DLBCL (single-arm phase II)
ChiCTR2600127766Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomalidomide, cyclophosphamide, doxorubicin, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Henan Cancer Hospital. Primary endpoint: Objective response rate at end of induction therapy. Started Jul 2026; status: recruiting.
02
Drugs
pomalidomidecyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2600127766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127766.